↓ Skip to main content

Dove Medical Press

Bioequivalence of a biosimilar enoxaparin sodium to Clexane® after single 100 mg subcutaneous dose: results of a randomized, double-blind, crossover study in healthy volunteers

Overview of attention for article published in Drug Design, Development and Therapy, March 2018
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (61st percentile)
  • Good Attention Score compared to outputs of the same age and source (70th percentile)

Mentioned by

policy
1 policy source
twitter
1 X user

Citations

dimensions_citation
9 Dimensions

Readers on

mendeley
42 Mendeley
Title
Bioequivalence of a biosimilar enoxaparin sodium to Clexane® after single 100 mg subcutaneous dose: results of a randomized, double-blind, crossover study in healthy volunteers
Published in
Drug Design, Development and Therapy, March 2018
DOI 10.2147/dddt.s162817
Pubmed ID
Authors

Javier Martínez González, Mayte Monreal, Ignacio Ayani Almagia, Jordi Llaudó Garín, Lourdes Ochoa Díaz de Monasterioguren, Ibón Gutierro Adúriz

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 42 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 42 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 8 19%
Student > Ph. D. Student 5 12%
Other 4 10%
Student > Bachelor 4 10%
Researcher 4 10%
Other 3 7%
Unknown 14 33%
Readers by discipline Count As %
Pharmacology, Toxicology and Pharmaceutical Science 10 24%
Medicine and Dentistry 6 14%
Nursing and Health Professions 5 12%
Agricultural and Biological Sciences 2 5%
Biochemistry, Genetics and Molecular Biology 1 2%
Other 4 10%
Unknown 14 33%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 September 2021.
All research outputs
#7,963,683
of 25,382,440 outputs
Outputs from Drug Design, Development and Therapy
#543
of 2,268 outputs
Outputs of similar age
#129,909
of 344,853 outputs
Outputs of similar age from Drug Design, Development and Therapy
#13
of 48 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. This one has received more attention than most of these and is in the 67th percentile.
So far Altmetric has tracked 2,268 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.1. This one has gotten more attention than average, scoring higher than 74% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 344,853 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 61% of its contemporaries.
We're also able to compare this research output to 48 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.